Lunit said on the 25th that it signed a partnership with Canada's CellCarta to use the artificial intelligence (AI) biomarker platform "Lunit Scope" in clinical trials. CellCarta is a global contract research organization (CRO). The company said that when pharmaceutical companies develop new drugs, AI can analyze biomarkers faster and more easily.
CellCarta has research facilities in the United States, China, and other locations. Yannick Bauman, head of CellCarta's digital pathology solutions, said, "Pharmaceutical corporations are looking for validated AI technologies to efficiently develop biomarkers and screen patients."
Seo Bum-seok, CEO of Lunit, said, "Lunit Scope can be widely used in clinical trials," adding, "We will help patients receive treatment more effectively."